240 related articles for article (PubMed ID: 23840376)
1. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Szulkin A; Nilsonne G; Mundt F; Wasik AM; Souri P; Hjerpe A; Dobra K
PLoS One; 2013; 8(6):e65903. PubMed ID: 23840376
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.
Barbone D; Cheung P; Battula S; Busacca S; Gray SG; Longley DB; Bueno R; Sugarbaker DJ; Fennell DA; Broaddus VC
PLoS One; 2012; 7(12):e52753. PubMed ID: 23300762
[TBL] [Abstract][Full Text] [Related]
4. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
Szulkin A; Otvös R; Hillerdal CO; Celep A; Yousef-Fadhel E; Skribek H; Hjerpe A; Székely L; Dobra K
BMC Cancer; 2014 Sep; 14():709. PubMed ID: 25253633
[TBL] [Abstract][Full Text] [Related]
5. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Giovannetti E; Zucali PA; Assaraf YG; Leon LG; Smid K; Alecci C; Giancola F; Destro A; Gianoncelli L; Lorenzi E; Roncalli M; Santoro A; Peters GJ
Br J Cancer; 2011 Nov; 105(10):1542-53. PubMed ID: 21970874
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
Cameron RB; Hou D
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):496-504. PubMed ID: 23174177
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
Habib EE; Fahmy ES
Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
[TBL] [Abstract][Full Text] [Related]
10. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
11. Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction.
Hwang KE; Kim YS; Hwang YR; Kwon SJ; Park DS; Cha BK; Kim BR; Yoon KH; Jeong ET; Kim HR
Int J Oncol; 2014 Oct; 45(4):1769-77. PubMed ID: 25096993
[TBL] [Abstract][Full Text] [Related]
12. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
13. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
14. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
Røe OD; Szulkin A; Anderssen E; Flatberg A; Sandeck H; Amundsen T; Erlandsen SE; Dobra K; Sundstrøm SH
PLoS One; 2012; 7(8):e40521. PubMed ID: 22905093
[TBL] [Abstract][Full Text] [Related]
15. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
[TBL] [Abstract][Full Text] [Related]
16. Malignant peritoneal mesothelioma in a child: chemotherapy with gemcitabine and platinum was effective for the disease unresponsive to other treatments.
Kobayashi S; Waragai T; Sano H; Mochizuki K; Akaihata M; Ohara Y; Hosoya M; Kikuta A
Anticancer Drugs; 2014 Oct; 25(9):1102-5. PubMed ID: 25010395
[TBL] [Abstract][Full Text] [Related]
17. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
Rolland D; Raharijaona M; Barbarat A; Houlgatte R; Thieblemont C
Anticancer Res; 2010 Oct; 30(10):3951-7. PubMed ID: 21036708
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
